Top ▲

Chronic neuropathic pain

Disease ID:222
Name:Chronic neuropathic pain
Associated with:1 target


Drugs:  ω-Conotoxin MVIIA (ziconotide)
Side effects:  Cognitive impairment, hallucinations, changes in mood and consciousness
Therapeutic use:  Opioid-unresponsive chronic pain
References:  1-5


No ligand related data available for Chronic neuropathic pain


Show »

1. Brose WG, Gutlove DP, Luther RR, Bowersox SS, McGuire D. (1997) Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain, 13 (3): 256-9. [PMID:9303259]

2. Mathur VS. (2000) A new pharmacological class of drug for the management of pain. Seminars in Anesthesia, Perioperative Medicine and Pain, 19: 67-75.

3. McGuire D, Bowersox S, Fellmann JD, Luther RR. (1997) Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol, 30 (3): 400-3. [PMID:9300326]

4. Penn RD, Paice JA. (2000) Adverse effects associated with the intrathecal administration of ziconotide. Pain, 85 (1-2): 291-6. [PMID:10692631]

5. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce DA, Mangieri EA, Luther RR et al.. (2004) Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA, 291 (1): 63-70. [PMID:14709577]